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Background: The considerable malaria decline in several countries challenges the strategy of chemoprophylaxis for
travellers visiting moderate- to low-risk areas. An international consensus on the best strategy is lacking. It is essential to
include travellers’ opinions in the decision process. The preference of travellers regarding malaria prevention for
moderate- to low-risk areas, related to their risk perception, as well as the reasons for their choices were investigated.
Methods: Prior to pre-travel consultation in the Travel Clinic, a self-administered questionnaire was given to travellers
visiting moderate- to low-risk malaria areas. Four preventive options were proposed to the traveller, i.e., bite prevention
only, chemoprophylaxis, stand-by emergency treatment alone, and stand-by emergency treatment with rapid diagnostic
test. The information was accompanied by a risk scale for incidence of malaria, anti-malarial adverse drug reactions and
other travel-related risks, inspired by Paling palettes from the Risk Communication Institute.
Results: A total of 391 travellers were included from December 2012 to December 2013. Fifty-nine (15%) opted
for chemoprophylaxis, 116 (30%) for stand-by emergency treatment, 112 (29%) for stand-by emergency treatment
with rapid diagnostic test, 100 (26%) for bite prevention only, and four (1%) for other choices. Travellers choosing
chemoprophylaxis justified their choice for security reasons (42%), better preventive action (29%), higher efficacy
(15%) and easiness (15%). The reasons for choosing stand-by treatment or bite prevention only were less medication
consumed (29%), less adverse drug reactions (23%) and lower price (9%). Those who chose chemoprophylaxis were
more likely to have used it in the past (OR = 3.0 (CI 1.7-5.44)), but were not different in terms of demographic, travel
characteristics or risk behaviour.
Conclusions: When travelling to moderate- to low-risk malaria areas, 85% of interviewees chose not to take
chemoprophylaxis as malaria prevention, although most guidelines recommend it. They had coherent reasons for their
choice. New recommendations should include shared decision-making to take into account travellers’ preferences.Background
For non-immune travellers or migrants, the strategy of
malaria prevention depends on the risk within the vis-
ited area, the season and the duration of stay [1], but
also on the policy of the country from where the traveller
sought advice before departure [2]. Although all countries
agree on prescribing chemoprophylaxis for high-risk
endemic regions, recommendations for moderate- to low-* Correspondence: Blaise.Genton@unibas.ch
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unless otherwise stated.risk areas, usually defined as a risk of one infection per
10,000 travellers [3], are variable [4-8]. Switzerland,
Austria, Sweden, The Netherlands, and Germany recom-
mend stand-by emergency treatment and bite prevention
[9,10] for these regions, whereas the majority of other
countries recommend chemoprophylaxis. The Center for
Disease Control recently replaced the term ‘stand-by
emergency treatment’ with ‘reliable supply regimen’, con-
sidering its use in exceptional circumstances only and
more as an adjuvant than an alternative to chemoprophy-
laxis [11].
In these moderate- to low-risk areas, taking chemo-
prophylaxis exposes travellers to a higher risk of severe
adverse drug reactions than actually being affected byal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0) which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Voumard et al. Malaria Journal  (2015) 14:139 Page 2 of 7malaria [12-14]. The frequency of mild to moderate ad-
verse drug reactions varies from 32-45% [15], underlining
the fragile balance between risks and benefits. The rather
low adherence of travellers to chemoprophylaxis (30-50%)
adds to the controversy about its relevance [16].
Little is known about the preference of travellers in
term of malaria prevention. Senn et al. highlighted the
importance of the price in travellers’ choice of one or
other medicine for chemoprophylaxis [17]. However, to
the knowledge of the authors, no study has addressed
the question of what would be the travellers’ choice in
terms of malaria prevention measures for moderate- to
low-risk areas, should alternatives be proposed to them.
In line with the current momentum of shared decision-
making [18], the present study aims at better under-
standing travellers’ aspirations. The primary objective
was to evaluate the personal preference of travellers
visiting moderate- to low-risk malaria areas, depending
on their perception of risk. The secondary objective was
to investigate the reasons for their choice, and correlate
it to their sociodemographic profile and risk behaviours.
Methods
The Travel Clinic in Lausanne is part of the Department
of Ambulatory Care and Community Medicine linked to
the University Hospital. Health professionals (physicians
and nurses) perform around 10,000 pre-travel consulta-
tions per year. All travellers attending the Travel Clinic
for a pre-travel consultation were screened for eligibility
by a research student. Included subjects were adults
without pre-travel consultation in the previous year who
were planning to visit moderate- to low-risk malaria
areas, as defined by the World Health Organization
(WHO) [8] with adaptation by the Swiss Federal Office
of Public Health (FOPH) [19].
Prior to the pre-travel consultation, four study docu-
ments were given to each traveller: a informed consent
form, a questionnaire, a table describing the four differ-
ent malaria prevention methods (see Additional file 1),
and a travel-related malaria risk scale. The questionnaire
included questions about the sociodemographic profile
and the travel pattern. Ten sociodemographic variables
were collected: gender, age, country of origin, occupation
(categorized according to the Occupational Classification
from the International Labour Organization (CITP-08)),
co-morbidities, usual treatments (including contracep-
tive pill), risk behaviours (alcohol consumption accord-
ing to the National Institute on Alcohol Abuse and
Alcoholism, active tobacco use and active or past drug
consumption, including cannabis), dependent child or
person at home, anti-malarial medication kept at home
or used before (as prophylaxis or treatment). Also, seven
variables concerning the type of travel were collected:
destination (subcontinent according to UN classification[20]), duration of stay, reason for travel (tourism, visiting
friends and relatives, humanitarian, business, expatriate),
travelling companions (couple, alone, group organized
by a travel agency, group outside a travel agency, family),
rural/urban areas (rural for < two weeks, rural for ≥ two
weeks, only urban, urban and rural, don’t know), and
delay to access medical care (<24 hr, ≥24 hr, don’t
know).
The traveller had to choose a malaria prevention
method and explain the reasons for the choice, on the
basis of a table describing four different options: 1) bite
prevention only (to wear long clothes, regular applica-
tion of mosquito repellent, mosquito net, to limit expos-
ition during high risk period); 2) chemoprophylaxis; 3)
stand-by emergency treatment; and, 4) stand-by emer-
gency treatment with rapid diagnostic test. This table
highlighted the main advantages and disadvantages of
each preventive strategy, and indicated its cost for a
two-week period (see Additional file 1: Table A). In
addition, the subject received a figure illustrating the risk
of malaria and the risk of anti-malarial adverse drug re-
actions compared to other travel-related risks (Figure 1).
The figure was derived from the Paling Palette from the
Risk Communication Institute [21]. The Paling Palettes
are designed to help healthcare improve the risk com-
munication to patients. This visual support is a decision
aid that compares absolute risk instead of relative one
[22,23]. A Swiss randomized study showed a higher level
of risk perception with Paling Palettes than with others
formats [24], yet with differences according to the edu-
cation level [25]. The traveller was then invited to again
choose a malaria preventive measure, should it be given
free of charge and give the reasons for choice. Five ques-
tions related to malaria (namely incidence, population at
risk, treatment, high-risk areas, and clinical manifesta-
tions) were also included to assess the traveller’s prior
knowledge about the disease.
Following data collection, all travellers received the
usual pre-travel advice by a physician or nurse according
to the standard procedures used at the Travel Clinic,
based on the Swiss FOPH guidelines.
For the qualitative data analysis, the reasons for each
choice were classified into 12 categories: travel risk
evaluation, security, efficacy, reactivity, easiness, price,
medication consumed, adverse drug reactions, medical
access, preventive action, diagnostic validation, peer
advice/previous experience, and others. All analyses were
descriptive. The investigation assessment of risk factors
was performed through bivariate analyses to calculate
odds ratio and confidence intervals. All data were
collected in Microsoft Excel and analysed using Epi Info
(CDC version 7.0). The protocol was approved by the
ethical review board of the University of Lausanne (No
441/12).
Figure 1 Travel-risk related scale, derived from the Paling Palette, Risk Communication Institute. [The 1:10 000 risk of malaria illustrated in
the figure describes the risk of malaria in moderate- to low-risk areas (WHO Malaria report 2011)].
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A total of 428 questionnaires were collected between
December 2012 and December 2013, and 391 (91%)
have been included. Thirty-seven (9%) travellers were
then excluded for the following reasons: destination to
malaria high or non-endemic areas (13); pre-travel con-
sultation in the previous six months (15); informed con-
sent not signed or dated (6); and, age under 18 years (3).
The sociodemographic data and the travel profile are
summarized in Tables 1 and 2. The 391 included travel-
lers had a median age of 36 years; 65% (255/391) visited
the Asian continent; 63% (247/391) for a duration be-
tween two and three weeks. The choice by travellers of
malaria prevention when taking into account the price is
shown in Figure 2: 15% (59/391) chose chemoprophy-
laxis (CP), 30% (116/391) stand-by emergency treatment
(SBET), 29% (112/391) stand-by emergency treatment
with rapid diagnostic test (SBET RDT), 26% (100/391) bite
prevention only (BP), 1% (4/391) CP + SBET or CP +
SBET RDT. When asked which method he/she would
choose if it was free of charge (Figure 3), 76% (295/390)
of travellers kept to their initial choice; 17% (68/391)chose CP (+2% when compared to first choice); 23%
(89/391) SBET (-7%); 42% (163/391) SBET RDT
(+13%); 16% (64/391) BP (-9%); and, 2% (6/391) CP +
SBET RDT (+1%) (one did not choose). Among the 100
travellers who had chosen BP when taking into account
the price, 34% (34/100) changed to SBET or SBET RDT
and 9% (9/100) changed to CP when free of charge.
Figure 4 describes the reasons given by travellers for
choosing CP and for choosing another preventive strat-
egy (namely SBET, SBET RDT and BP). Those choosing
CP mentioned security (42%), preventive action (29%)
and both efficacy (15%) and easiness (15%) as reasons,
while those who did not choose CP mentioned less
medication consumed (29%), less adverse drug reactions
(23%) and price (9%). Only the previous use of anti-
malarial was significantly associated with CP (versus
another choice) (OR 3.0 (95% CI 1.7-5.4). For these travel-
lers who already used anti-malarial medicine (as prophy-
laxis or treatment), 28% (29/105) chose CP (+18% when
compared with naive travellers), 32% SBET (+3%), 23%
(24/105) SBET RDT (-8%), 16% (17/105) EP (-14%), and
1% (1/105) no prevention. In term of socio-demographic
Table 1 Socio-demographic characteristics of the 391
travellers included
Socio-demographic characteristics Frequency %
Gender female 54% (212)
Age category (years)
18-25 25%(98)
26-30 26% (101)
31-40 22% (86)
41-50 10% (41)
>50 17% (65)
Country of origin
Switzerland (CH) 67% (263)
Out of CH, endemic for malaria 4% (17)
Out of CH, non endemic for malaria 22% (85)
Unknown 7% (26)
Occupation
Managers and intellectual formation 28% (107)
Intermediate training 11% (44)
Administrative or technical training 28% (111)
Farmers, workers, artisans 4% (17)
Students 17% (67)
Jobless, pensioners or unknown 12% (45)
Co-morbidities 13% (52)
Usual treatment (including pill) 24% (95)
Risk behaviours (OH, tobacco, drugs)
Having 1 risk behaviour 26% (101)
Having 2 risks behaviours 12% (47)
Having all 3 risks behaviours 3% (13)
Dependent child or person at home 12% (45)
Anti-malarial medicine kept at home 15% (59)
Anti-malarial medicine used before
as prophylaxis or treatment 27% (105)
Table 2 Travel characteristics of the 391 travellers included
Travel characteristic Frequency %(n)
Destination 45% (177)
South-Eastern Asia 20% (78)
Southern Asia 24% (94)
South America 24% (94)
Carribbean and Central America 4%(15)
Africa (United Republic of Tanzania only)* 5% (20)
Round the world 2% (7)
Duration of stay
1 week 6% (25)
2-3 weeks 63% (247)
4-6 weeks 12% (48)
6-12 weeks 5% (21)
>3 months 13% (50)
Reason of travel
Tourism 83% (324)
Visiting friends and relatives (VFR) 9% (35)
Humanitarian 3% (13)
Business 3% (13)
Expatriate 1% (3)
Travelling companions
Couple 42% (166)
Alone 20% (77)
Group organized by a travel agency 17% (67)
Group outside a travel agency 11% (44)
Family 8% (32)
Unknown 1% (5)
Rural/urban areas
Rural for <2 weeks 29% (114)
Rural for≥ 2 weeks 18% (72)
Only urban 14% (53)
Urban and rural 8% (30)
Don’t know 31% (121)
Delay to access medical care
<24h 21% (84)
≥24h 18% (71)
Don’t know 58% (228)
Unknown 2% (8)
Delay to access medical care
0-1 25% (96)
2-3 51% (200)
4-5 24% (24)
*All these travellers were visiting Zanzibar with a stop-over in Dar es Salaam.
Zanzibar is known to have moderate to low endemicity, and is, therefore, the
only area in sub-Saharan Africa where stand-by treatment rather than prophylaxis
is recommended according to the Swiss Federal Office of Public Health
recommendations.
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the past were older (median age 42 vs 34 years old) and
had a better knowledge of the disease (41% vs 18% of
appropriate responses). For travellers having a dependent
person at home and those travelling to Tanzania, the OR
for CP was borderline: 1.8 (CI 0.8-3.8) and 2.4 (CI 0.9-6.4),
respectively. No other sociodemographic or travel charac-
teristic was associated with CP.
Discussion
When provided with an illustrative figure that compared
the risk of malaria, the risk of adverse drug reactions,
and other travel-related risks, the travellers chose stand-
by emergency treatment with or without rapid diagnos-
tic test in first place (58%) followed by bite prevention
only (26%), while only 15% chose chemoprophylaxis. If
Figure 2 Travellers choices regarding preventive strategies
against malaria (n=391). CP= Chemoprophylaxis, BP only= Bite
prevention only, SBET= Stand-by emergency treatment, SBET
RDT= Stand-by emergency treatment with rapid diagnostic tests,
Other= CP+SBET+/- RDT.
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travellers would have chosen the same method. No rec-
ommendation on malaria prevention currently includes
travellers’ preferences. Considering the growing trend
towards shared decision-making in healthcare, the high
rate of travellers opting for not taking chemoprophylaxisFigure 3 Travellers choices regarding preventive strategies against
malaria if prevention is free (n=391). CP= Chemoprophylaxis, BP
only= Bite prevention only, SBET= Stand-by emergency treatment,
SBET RDT= Stand-by emergency treatment with rapid diagnostic tests,
Other= CP+SBET+/- RDT.calls for an adaptation of the guidelines to integrate trav-
ellers’ preferences.
The choice made by the traveller was coherent with
the reason he/she gave to support his/her preferred
option. The 15% of travellers who chose CP mentioned a
‘higher level of security’ and the ‘preventive action’ as
main reasons, whereas the 85% of travellers who chose
SBET +/- RDT or BP mentioned ‘fewer medication
intake’ and ‘fewer adverse drug reactions’. Although not
formally studied using a control group, the use of a risk
scale inspired by Paling Palette probably helped the trav-
eller to understand and perceive better his/her own risk.
These findings indicate that the traveller is able to assess
risk according to his/her perception and to weigh his/
her own priorities. This is the essence of the shared
decision-making process between client and health pro-
fessional. One of the main challenges of shared decision-
making is to create tools to « diagnose preference » [26].
As the author says, this approach insures that patients
or travellers get « the care they need and no less, the
care they want and no more ». In this relational process,
healthcare recognizes the patient’s own expertise, design
by experience of illness, social circumstances, attitude to
risk, values and preferences [27]. Some travellers prefer
to take a high but not severe risk of anti-malarial adverse
event, some others prefer a low but severe risk of having
a malaria. The healthcare professional requires advanced
communication skills to present the risks and the differ-
ent options, and decision aid can be a tool [28]. In the
present study, the travellers having previous experience
of anti-malarial use in the past were feeling more com-
fortable with the medication risk than with the malaria
risk as they were more likely to choose CP as prevention
compared to the naive travellers.
The traveller’s choice should not be the main criterion
to decide which recommendation to propose. However,
his/her opinion should be integrated into the decision
process, as recommended in the WHO Guidelines Review
Committee [29]. For malaria prevention, the consumer’s
perspective has never been considered, which could
explain the rather low adherence to the recommendations,
especially to chemoprophylaxis [15]. SBET is one among
several options, but certainly not the sole one. Adding
rapid diagnostic tests (RDTs) might improve appropriate-
ness of SBET use when a traveller is febrile. This needs to
be investigated further and a study is ongoing in the
Travel Clinic to assess travellers’ behaviour and satisfac-
tion with this new diagnostic tool.
Caution should be applied since the present study has
been conducted in a country where SBET is recom-
mended for travellers visiting moderate- to low-risk mal-
aria areas. One can thus consider that the people included
in the study were familiar with the Swiss malaria preven-
tion policy and more open to taking risks than other
Figure 4 Travellers reasons for choosing chemoprophylaxis or another preventive strategy (n=391). CP= Chemoprophylaxis, No CP= No
Chemoprophylaxis, BP only= Bite prevention only, SBET +/- RDT= Stand-by emergency treatment +/- rapid diagnostic test.
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patient-centered perspective, defined by the Common-
wealth Fund’s National Scorecard as ‘care delivered with
the patient’s needs and preferences in mind’ [30], and
where Switzerland is scored second in world ranking of
health care systems by the Commonwealth Fund [31].
Conclusions
The findings of this study call for more consideration of
travellers’ opinions and desires when establishing guide-
lines. As long as information is provided adequately, the
traveller can take more responsibility for his/her own
health, according to his/her own risk perceptions and
beliefs. The latter should not be the only criterion, but
one component of an integrated decision process. Such
an approach may both increase adherence to malaria
preventive measures and raise the credibility of travel
medicine advisors across countries.
Additional file
Additional file 1: The main advantages and disadvantages of four
preventive strategies.
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